NanoRepro AG (ETR:NN6)
Germany
· Delayed Price · Currency is EUR | Market Cap | 19.80M |
| Revenue (ttm) | 5.17M |
| Net Income (ttm) | -1.72M |
| Shares Out | 12.61M |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,805 |
| Average Volume | 8,526 |
| Open | 1.580 |
| Previous Close | 1.570 |
| Day's Range | 1.530 - 1.600 |
| 52-Week Range | 1.165 - 2.120 |
| Beta | 0.32 |
| RSI | 62.25 |
| Earnings Date | Jun 5, 2026 |
About NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preventive healthcare line products. The company also develops and commercializes immunochromatographic lateral flow tests; and tests for hospitals and medi... [Read more]
Financial Performance
In 2024, NanoRepro AG's revenue was 4.51 million, an increase of 41.68% compared to the previous year's 3.18 million. Losses were -2.05 million, -56.34% less than in 2023.
Financial StatementsNews
NanoRepro raises its equity stake in Deutsche Kosmetikwerke: NanoRepro raises its stake in DKW to 43.72%. ...
Yesterday, NanoRepro announced an increase in its direct equity stake in DKW alongside its FY25p revenue figures. In detail: A step on the way to building a strong multi-brand platform. NanoRepro r...
NanoRepro raises its equity stake in Deutsche Kosmetikwerke
NanoRepro raises its stake in DKW to 43.72%. FY25 sales came in ahead of guidance and support the positive outlook. We reiterate BUY with a PT of € 4.3.
From tests to brands, revamping NanoRepro; INITIATE with BUY
NanoRepro transforms into a multi-brand health platform post-pandemic, with strong growth potential from its diverse portfolio and M&A. Initiating coverage with a BUY and € 4.3 price target.